the MACE RRR benchmark is really 38%, not 25%, due to the low HDL restriction
Might be helpful to clarify the source for your statement - In R-It, the RRR was 38% in the high TG/low HDL group most comparable to STRENGTH trial population. I agree that the labeling of epanova will have to be more restricted than V as a result of their inclusion criteria.